Journal of Hebei Medical University

Previous Articles     Next Articles

Clinical analysis of 89 cases of acute ischemic stroke who accepted rtPA intravenous thrombolysis

  

  1. Department of Neurology, the Third Hospital of Xingtai City, Hebei Province, Xingtai 054000, China
  • Online:2017-04-25 Published:2017-04-25

Abstract: [Abstract]  Objective〖HTSS〗〓To evaluate the efficacy safety of intravenous thrombolysis(rtPA), and to analysis the factors that influence the prognosis of patients.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The clinical data of 89 patients with acute cerebral infraction who accepted rtPA, and the factors that affect efficacy and safety of rtPA were retrospetively analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓There were 47 patients with favorable function outcome accounted for 52.81% after thrombolysis immediately, and 56 patients with favorable function outcome accounted for 62.92% at 7 days after thrombolysis. It has shown that the prognosis was better in the younger group than the elderly group(P<005), and in the lower National Institute of Health Stroke Scale(NIHSS) score group than higher group before thrombolysis, and in the shorter door to needle time group than the longer group by comparing Modified Rankin Scale(mRS) score in 3 months. Compared with the group without intracranial hemorrhage,in intracranial hemorrhage group, the NIHSS score was higher,the door to needle time was longer,the rate of atrial fibrillation was higher.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓It is efficacy and safety to give intravenous thrombolysis therapy with rtPA to patients with acute cerebral infraction. The younger of the patients,the lower NIHSS score before thrombolysis,the shorter of the door to needle time indicate better prognosis after 3 months. In addition, the NIHSS score before thrombolysis,the door to needle time and atrial fibrillation were the risk factor that influence intracranial hemorrhage after thrombolysis, but intracranial hemorrhage did not affect the prognosis after 3 months.

Key words: brain infarction, tissue plasminogen activator, prognosis